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1. 
NMR METHOD FORMONITORING 
CHANGES IN THE CORE OF LIPOPROTEIN 
PARTICLES IN METABOLISMAND 
DISEASE 
BACKGROUND 
The present invention relates to the analysis of blood to 
identify and measure properties that correlate with cardio 
vascular disease. 
Cardiovascular disease primarily in the form of heart 
attack or stroke is the leading cause of death in the United 
States and other developed countries. Cardiovascular dis 
ease is likewise becoming an increasing cause of death in 
developing countries as the risk of death from infectious 
diseases decreases in Such countries. 
Some of the main risk factors associated with cardiovas 
cular disease are generally well understood. They include an 
elevated amount of low density lipoprotein (LDL), high 
blood pressure, cigarette Smoking, diabetes mellitus ("dia 
betes'), family history, and a less physically active, more 
sedentary lifestyle. 
Serum LDL cholesterol levels are positively correlated 
with cardiovascular disease risk. However, approximately 
half of patients who suffer from symptomatic coronary 
artery disease have normal LDL-cholesterol concentrations. 
Therefore, there appears to be a hidden risk not detected by 
conventional clinical laboratory measurements of choles 
terol. 
As currently best understood, cholesterol deposited in 
arteries represents a main factor in cardiovascular disease. 
Cholesterol is effectively insoluble in water and blood and 
thus the body carries cholesterol using particles called 
lipoproteins. The body uses several lipid transporting par 
ticles present in blood and these lipoprotein particles are 
typically referred to as chylomicrons, very low density 
lipoproteins (VLDL), intermediate density lipoproteins 
(IDL) and high density lipoproteins (HDL). Density 
increases when less cholesterol is present and density 
decreases when more cholesterol is present. Thus, the lay 
man often refers to LDL cholesterol as “bad” cholesterol and 
HDL cholesterol as “good cholesterol. 
Low density lipoprotein particles tends to deposit in artery 
walls to form atherosclerotic plaques in the artery. In turn, 
the deposition of LDL to form the atherosclerotic plaques is 
promoted by an increased LDL concentration (or remnants 
that can form LDL particles) and a decreased LDL particle 
S17C. 
In order to help predict and potentially moderate or avoid 
cardiovascular disease in individuals, conventional clinical 
tests are carried out to measure certain of the known risk 
factors. Currently, the most common test is the basic lipid 
panel which measures total cholesterol, HDL cholesterol 
(“HDL-C), and triglycerides. The LDL cholesterol (“LDL 
C’) is calculated as the difference between total cholesterol 
and HDL cholesterol. 
Currently, approximately 250,000,000 such tests are car 
ried out in the United States every year, and on a worldwide 
basis 540 million tests are carried out each year. Current 
costs are between about $26 and S56 per test. 
As an additional factor, LDL can be present in different 
LDL particle sizes. In turn, smaller LDL particle sizes are 
associated with an increased risk of cardiovascular disease. 
Because of the size relationship, information about the size 
of the LDL particles is valuable in combination with infor 













Currently, the common tests for measuring LDL particle 
size include vertical autoprofile (VAPR), gradient gel elec 
trophoresis, and NMR lipoprofiles. 
VAP is also referred to as a vertical spin density gradient 
ultracentrifugation and an exemplary version (“The VAP 
Cholesterol Test(R) is provided by Atherotech, Inc. of 
Birmingham, Ala. (USA). 
Gradient gel electrophoresis distinguishes particle size in 
a otherwise conventional electrophoresis (i.e. chromatogra 
phy) process with an exemplary test offered by Berkeley 
HeartLab Inc. of (South San Francisco Calif. (USA). 
In one commercial embodiment, NMR lipoprofile testing 
is based upon the chemical shift of the resonant frequencies. 
LipoScience Inc. (Raleigh, N.C. USA) is an exemplary 
provider of such tests, a number of which are based on U.S. 
Pat. No. 5,343,389 (and others) to James D. Otvos (“the 
Otvos patents'). The Otvos patents employ frequency-do 
main FT-NMR to study lipoprotein particle properties, such 
as particle size and particle number, in order to perform 
clinical diagnostic testing and disease risk assessment. In 
order to provide accurate data, however, chemical shift 
NMR is typically carried out in large (e.g., 400 megahertz or 
higher) high resolution Fourier-transform NMR instruments. 
Many Such instruments incorporate a Superconducting mag 
net cooled by a Surrounding environment of liquid helium 
which in turn is surrounded by liquid nitrogen. As a result, 
the device is large and expensive and the testing is carried 
out in a small number of central laboratories at a cost of 
between about 100 and $200 per test. 
Such tests also require a frequency-domain analysis, 
typically performed by a Fourier transform of the data. The 
key measurable is the chemical shift, a measure of relative 
frequency and atomic environment. Differences in chemical 
shifts are used to distinguish and resolve different lipopro 
tein classes and permit the detection of particle size and 
number. 
In evaluating an individual’s lipid profile, core mobility or 
fluidity of the lipids is a reflection of the relative ratio of 
different cholesteryl ester and triglyceride molecules in the 
particle core, which in turn, is a reflection of normal or 
abnormal lipid metabolism. 
Lipoproteins are the body's nanoparticle delivery systems 
that carry water-insoluble cholesterol and triglyceride mol 
ecules through the blood and target them to particular tissues 
for metabolism. Lipoprotein particles can be distinguished 
by their density, size, chemical composition and charge. 
They can also be distinguished by the relative lipid content 
of the particle's oily core compartment. For example, the 
cores of LDL and HDL are relatively rich in cholesteryl ester 
(a highly water-insoluble form of cholesterol), whereas 
VLDL and chylomicrons are relatively rich in triglycerides. 
Triglyceride molecules are more flexible than cholesteryl 
esters, so oil phases rich in triglycerides will appear more 
fluid and mobile, less viscous. Also, the ratio of these 
components and thus, the core mobility, changes with 
metabolism and disease. 
On a broad basis, the use of NMR techniques for medical 
purposes is not new, and the term "NMR typically can refer 
to a variety of diagnostic methods. There are many types of 
NMR methods and instruments and thousands of distinct 
NMR experiments. A vivid example of this is magnetic 
resonance imaging (MRI), which was originally called 
NMR Imaging. MRI is a variation of NMR that yields 
anatomical images rather than chemical signatures. 
Although MRI is based on the same fundamental physics, it 
involves different instrumentation, methods and derived 
measurable from other NMR techniques. Thus, different 
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kinds of NMR are used in somewhat related but distinct 
areas of medical diagnosis, imaging, and treatment. 
U.S. Pat. No. 7,550,971 B2) to Carpenter and Benson 
describe a method of determining analyte concentrations in 
body fluids Such as blood plasma or serum, examples given 
in the claims are the concentrations of glucose, cholesterol, 
triglycerides, albumin, blood urea nitrogen, alkaline phos 
phatase and creatinine. The method is restricted to the use of 
low-field, bench-top TD-NMR instruments, but the mea 
Surements and derived quantities are analyte concentration 
rather than lipoprotein core mobility. These contrasting 
measurables provide completely different types of diagnos 
tic information. 
Arguably, the Carpenter and Benson methods are thinly 
justified and lack any preliminary data that demonstrates the 
feasibility of their method for measuring analyte concentra 
tions, and bench-top TD-NMR may not be as suitable for 
measuring the analyte concentrations as Carpenter and Ben 
son imply. Serum is a complex mixture, and U.S. Pat. No. 
7.550,971 lacks any explanation as to how the different 
analytes in serum can be resolved from one another. Instead, 
much of the content in U.S. Pat. No. 7,550,971 reflects the 
known operation of the TD-NMR instrument rather than a 
technique for resolving analytes from TD-NMR data. 
As a result of these various factors, vertical autoprofile, 
gradient gel electrophoresis, and NMR lipoprofiles can be 
impractical for routine clinical use; i.e., they are too expen 
sive and too cumbersome to be carried out on-site in a 
practitioner's office or a hospital laboratory. 
As another factor, various lipid tests (e.g., for HDL-C and 
LDL-C) can be inaccurate in certain circumstances. For 
example, calculated LDL-C values from a conventional lipid 
panel are not accurate when determined from non-fasting 
blood samples or in patients who have elevated triglyceride 
levels, as is common in diabetes. Likewise, some advanced 
lipid tests like the NMR LipoProfile require fasting blood 
samples and thus, cannot monitor changes in lipoprotein 
particles during metabolism following a meal. 
Furthermore, evidence is beginning to emerge that char 
acteristics of lipid-carrying particles other than size and 
density will correlate with an increased risk of cardiovas 
cular disease. 
As yet another factor, when any particular test is difficult 
to carry out, or must be carried out off-site, or will take 
significant time to complete, or any combination of these 
factors, the use of that test will tend to be less frequent than 
the use of tests that can be carried out quickly and easily at 
a location—a physicians office, Small clinic, or hospital— 
where patients are typically located and their blood samples 
taken. 
Thus, tests that identify cardiovascular risk and that can 
be carried out more quickly, more easily, less expensively, 
and on site would tend to be used more frequently and thus 
provide greater benefits to individual patients and to the 
relevant patient population. 
Therefore, a need exists for faster, similar and localized 
techniques that will identify and measure relevant charac 
teristics that correlate to an expected degree of risk of 
cardiovascular disease. 
SUMMARY 
This invention describes non-perturbing methods for 
monitoring changes in the core mobility and core composi 
tion of lipoprotein particles in intact, unfractionated body 














In one aspect, the method includes the of placing a small 
volume of a sample into a NMR instrument tuned to measure 
a particular nucleus, applying a series of radiofrequency 
pulses with intermittent delays in order to measure spin-spin 
(“T”) and/or spin-lattice (“T) relaxation time constants 
from the time-domain decay of the signal, without the use of 
chemical shifts and without converting data into the fre 
quency domain by Fourier transform or other means, at least 
partially Suppressing the water signal prior to the beginning 
of a sequence used to record relaxation time constants in the 
time domain, optionally utilizing relaxation contrast agents 
or other chemical additives to perturb the solvent water or 
other elements of the sample, analyzing the exponentially 
decaying NMR signal in the time domain using multi 
exponential analysis, and comparing differences in the relax 
ation time constants for lipoprotein- or protein-specific 
elements within a single human Subject, or between subjects, 
to assess normal and abnormal metabolism reflective of 
increased disease risk or active disease. 
In another aspect, the method comprises measuring the 
pulsed time domain NMR spin-spin relaxation time for a 
plurality of LDL samples, normalizing the viscosity of the 
same LDL samples, plotting the product of spin-spin relax 
ation time and Viscosity for the samples against an axis 
defined by spin-spin relaxation time to thereby develop a 
database of T or TV statistics (or T or TV statistics or 
some combination of T, TV, T, or TV) for the original 
LDL samples, measuring the classic lipoprotein profile for 
the same LDL samples, and correlating known risks of 
cardiovascular disease based upon the classic lipoprotein 
testing with the results as determined by the T or TV 
statistics to thereby correlate the T or TV statistics with the 
known risks of cardiovascular disease in a statistically 
acceptable manner. As used herein, the term “normalizing 
the Viscosity of the sample comprises either using samples 
at the same Viscosity by physically manipulating the samples 
to obtain the Viscosity; or mathematically modeling the 
resulting data so that the results are comparable across 
viscosities. Persons skilled in the art are familiar with both 
techniques and they are not otherwise described in detail 
herein. 
Without being bound by theory, the possibility exists that 
the relevant interpretation of the NMR data can be obtained 
regardless of normalization; i.e., the Viscosity normalization 
may be option or unnecessary. Thus, where appropriate the 
phrase “T or TV” reflects this. 
In another aspect, the invention is a diagnostic kit that 
includes a pulse time domain NMR instrument, a sample 
selected from the group consisting of serum and plasma, and 
a database of T or TV data that correlates with known 
cardiovascular risk statistics. 
In another aspect, the invention is a combinatorial library 
that includes a plurality of patient samples selected from the 
group consisting of whole or partially fractionated serum or 
plasma, and a T or TV measurement for each sample. 
In another aspect, the invention is a method of determin 
ing cardiac risk factors based upon blood samples. The 
method includes the steps of measuring the pulse time 
domain NMR spin-spin or spin-lattice relaxation time of a 
sample selected from the group consisting of serum and 
plasma, measuring the lipid profile of the same sample, 
optionally combining the spin-spin relaxation time and 
viscosity of the sample to produce a T or TV value for the 
blood sample, and comparing the T or TV value to the lipid 
profile of the sample to identify the cardiac risk measured by 
the T or TV value based upon the cardiac risk measured by 
the lipid profile. 
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BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a very general Schematic diagram of an LDL 
particle and its internal oil phase. 
FIG. 2 is a TD-NMR T, profile for purified human 
low-density lipoprotein at 25°C. 
FIG. 3 is a plot of metabolic remodeling of LDL core 
lipids during metabolism following a meal. 
FIGS. 4-6 are CONTIN profiles for pure triolein and for 
two lipid cores. 
FIG. 7 is a plot of TV values for albumin, LDL plus 
albumin, and VLDL plus albumin. 
FIG. 8 is a plot of TV values for three samples of whole 
human serum. 
FIG. 9 is a plot of TV values for lipoprotein particles at 
various times after a meal. 
DETAILED DESCRIPTION 
The methods of the invention resolve individual lipopro 
tein particle classes (e.g., low-density lipoprotein or LDL) 
by detecting differences in core lipid mobility, which is 
influenced by the relative amount of cholesteryl ester to 
triglyceride molecules within each particle's core. Variabil 
ity in core mobility and core composition within a particle 
class. Such as LDL, can result from patient-to-patient dif 
ferences, or from particle remodeling within an individual 
Subject as occurs during metabolism following a meal. 
Changes in lipoprotein particle core mobility and core 
composition are monitored using a time-domain nuclear 
magnetic resonance (TD-NMR) analysis. A hallmark of this 
approach is that the analysis is performed without Fourier 
transformation and without the use of frequency-domain 
information Such as chemical shifts. Unlike frequency 
domain Fourier-transform NMR, this time-domain NMR 
analysis can be performed at low magnetic fields (sG0 MHz 
for hydrogen) in a low-cost, bench-top instrument configu 
ration, although it can also be performed in conventional 
high-field NMR spectrometers. 
The general principles of time domain pulse NMR are 
generally well understood and familiar to persons of ordi 
nary skill in the art and need not be discussed in detail. In 
brief, however, a sample is positioned in an external mag 
netic field provided by a permanent magnet. This aligns the 
magnetic moments of the hydrogen atoms with (or against) 
the permanent magnetic field. Then, a radio frequency pulse 
is applied in a direction that provides a secondary (tempo 
rary) magnetic field perpendicular to the permanent mag 
netic field. This moves the magnetic moments of the hydro 
gen atoms away from their equilibrium state. The time 
duration of the pulse determines how far the magnetic 
moments move. The combined movement of many spins 
(many hydrogen atoms) generates a small but detectable 
oscillating magnetic field that in turn induces an alternating 
voltage that is measured as the NMR signal by a detection 
coil. 
At the end of the pulse, the protons in the sample give up 
excess energy to their surroundings and relax back to the 
equilibrium state with respect to the permanent magnetic 
field. This relaxation takes a certain amount of time, so that 
the NMR signal remains detectable for a period of time that 
can range from several milliseconds to several seconds. 
Furthermore, the relaxing component of the NMR signal 
will be characteristic of individual mobility domains, which 













For example, cholesterol molecules are more internally rigid 
than triglyceride molecules and will tend to give lower T. 
and T values. 
Additionally, the data resolution of the pulse time domain 
NMR technique of the invention is on the order of particle 
size. In comparison, Fourier transfer NMR resolves data on 
an atomic scale. As a result, the time domain technique 
makes fewer technical demands (so to speak) on the instru 
ment and can provide useful data at the available resolution. 
According to the invention, it is been determined that time 
decay constants are sensitive to both particle size and 
particle mobility. 
The method is also tolerant of multiple phases or mixed 
phases; i.e., Solids and liquids in many circumstances. 
As part of the correlation discoveries of the invention, it 
is now been determined that LDL particles with a higher 
triglyceride/cholesterol molecular ratio in the core have a 
longer spin-spin relaxation time (T) and particles with a 
lower triglyceride/cholesterol ratio have a shorter T. 
Although the inventors do not wish to be bound by a 
particular theory, it appears that this may result from the 
characteristics of an LDL particle as not being Solid in the 
same sense as a solid homogeneous composition would be. 
Instead, the LDL particle has an internal oil phase (FIG. 1). 
In turn, the oil phase moves (tumbles) differently—and 
typically faster than the remainder of the particle. This 
faster internal tumbling increases the spin-spin relaxation 
time. 
In one embodiment, the hydrogen spin-spin relaxation 
rate constants (or time constants) are measured using a 
low-field bench-top time-domain NMR analyzer, and the 
relaxation rate constants for individual lipoprotein classes 
are resolved through a multi-exponential deconvolution 
algorithm. Another key feature of this analysis is that 
measurements can be made directly on intact body fluids 
(e.g., serum, plasma or blood) without the need for separa 
tion or fractionation of individual lipoprotein classes by 
ultracentrifugation, electrophoresis, chromatography or 
other time-consuming, sample-perturbing methods. Because 
of the relative simplicity and low cost, this method has 
potential application to clinical testing for the detection of 
unique dyslipidemias and for the early detection and risk 
assessment of cardiovascular disease, diabetes and cancer. 
The measurements can, of course, be made in conven 
tional high-field NMR spectrometers, but as set forth herein, 
the use of Benchtop instruments offers a number of clinical 
advantages. 
In the invention, time-domain NMR resolves individual 
lipoprotein classes by measuring mobility differences in the 
oil phases within the core compartment of lipoprotein par 
ticles. The invention is also based on the discovery that 
TD-NMR is sensitive to changes in the particle core within 
a lipoprotein class. For example, the LDL particles in 
diabetic subjects tend to be richer in triglyceride, which 
makes the particle core more mobile. 
The mobility differences are monitored by measuring 
relaxation rate constants (or time constants) without chemi 
cal shifts. Chemical shifts are the centerpiece of conven 
tional high-field, frequency-domain NMR. By contrast, 
time-domain NMR does not require chemical shifts for 
frequency domain resolution and does not require high 
magnetic field strength or field homogeneity. This approach 
is fundamentally different from conventional NMR spec 
troscopy in both methodology and instrumentation require 
mentS. 
In one embodiment, the invention is a process for mea 
Suring the spin-spin or transverse relaxation time constants 
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(T) for the lipid core compartments in unfractionated 
human serum. The human serum is obtained in a conven 
tional manner from a low-speed centrifugation of human 
blood after clotting. Approximately 0.6 mL of unmodified 
serum is pipetted into a 10 mm NMR tube, and the tube is 
placed into the bore of the magnet of a bench-top TD-NMR 
analyzer, typically operating at 10, 20, 40 or 60 MHz 
resonance frequency for hydrogen. In the examples 
described here, 20 MHZ and 40 MHZ data were collected 
using Bruker benchtop md20 and md40 TD-NMR instru 
ments (Bruker BioSpin Corporation, Billerica, Mass., USA). 
A Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence is 
used to measure the exponential time-decay curve. This 
pulse sequence effectively eliminates chemical shifts and 
magnetic field inhomogeneity, permitting the measurement 
of T values. Although T. measurements can be linked with 
chemical shifts and measured in the frequency domain, the 
present TD-NMR method measures T. in the time domain 
without chemical shifts. This provides a distinct advantage 
with respect to instrument simplicity and cost. 
The resulting T decay curve for human serum is multi 
exponential, so the individual exponential terms are decon 
voluted and resolved with the use of an inverse Laplacian 
transform. An implementation of this mathematical calcu 
lation is provided in the public domain software CONTIN, 
authored by Steven Provencher (http://s-provencher.com/ 
pages/contin.shtml; accessed Mar. 11, 2013). Under the 
proper experimental conditions with excellent signal-to 
noise, the CONTIN calculation can resolve up to 8 different 
exponential terms in TD-NMRT2 profiles of human serum. 
Because human serum has abundant quantities of lipoprotein 
core lipids and soluble proteins, and because these assem 
blies are relatively large, the protein and lipoprotein com 
ponents dominate the T profile. 
One experimental issue involves solvent Suppression, 
because an intense water signal can overshadow the contri 
butions of lipoprotein components and lead to artifacts Such 
as radiation damping. The solvent water can be partially 
suppressed using a number of NMR schemes. In this 
embodiment, a 180-degree pulse and delay is inserted prior 
to the CPMG sequence. This achieves partial relaxation (and 
partial suppression) of the water with full recovery of the 
lipoprotein components by the start of the CPMG pulse 
scheme. Although there are many sophisticated NMR meth 
ods for Suppressing water, the goal of this invention was to 
develop the simplest, most inexpensive method for measur 
ing lipoprotein core properties in unmodified human serum. 
This embodiment is further illustrated using the figures 
and tables. FIG. 2 shows a time-domain T. NMR profile of 
normal fasting human serum, and FIG. 3 is the TD-NMRT 
profile for purified human low-density lipoprotein at 25°C. 
The profile of FIG. 2 (not to be confused with a conven 
tional NMR spectrum) was obtained by performing an 
inverse Laplacian transform of the T decay curve. In turn, 
the T curve was measured using a modified CPMG experi 
ment on a Bruker 40 MHz TD-NMR analyzer. The profile 
resolves 7 distinct T components, here represented as peaks 
in the profile. Higher T values represent more mobile 
elements. The solvent water peak in serum, not shown in this 
plot, is observed at T values of approximately 600 ms. The 
peaks at approximately 200 and 70 ms represent two distinct 
mobility domains in LDL, as assigned from control samples 
containing only LDL. 
These two peaks are not observed in the other control 
samples containing fractionated serum proteins or lipopro 














lipid mobility of LDL. The peaks at lower T values have 
contributions from both serum proteins and lipoproteins. 
FIG. 9 illustrates the variation in T. measurements in 
response to metabolic changes following a meal. Shown are 
T profiles for whole human serum at fasting, 2 hours, 4 
hours and 6 hours post-prandial. The T values for the 
LDL-specific peaks increase and peak at 4 hours, reflecting 
the remodeling of the LDL core as the content of triglyceride 
increases relative to cholesteryl ester. 
These preliminary results demonstrate the feasibility of 
obtaining particle-specific measurements of the core mobil 
ity of LDL in whole human serum. The data also demon 
strate that T. measurements obtained from TD-NMR are 
sensitive to metabolic remodeling and patient-to-patient 
variability. 
Furthermore, the invention requires neither high magnetic 
field instrumentation nor a frequency-domain analysis. 
Instead, it uses a time-domain analysis. Unlike (for example) 
the Otvos approach, the methods of the invention can be 
performed on inexpensive low-field bench-top instruments, 
because high field strength and field homogeneity is not 
required. The key measurables are relaxation rate constants 
rather than chemical shifts. Differences in relaxation rate 
constants are used to resolve lipoprotein classes (not chemi 
cal shifts, as in Otvos and Kremer). Also, the derived 
parameter in our invention is lipoprotein particle core mobil 
ity or fluidity, rather than particle number or particle size. In 
Summary, the instrumentation, data processing, measurables 
and derived parameters of our invention are different from 
those of Otvos. 
In contrast to (for example) U.S. Pat. No. 7,550,971, the 
present invention does not measure analyte concentrations. 
Rather it measures lipoprotein particle properties, specifi 
cally the mobility or fluidity (“squishiness') of the oily lipid 
core found within lipoprotein particles. Also, the invention 
is not restricted to low-field, bench-top NMR instruments, 
but can also be performed on conventional high-resolution 
NMR instruments as well. 
Overall, the method of the invention is much simpler and 
can be performed on inexpensive low-field benchtop NMR 
analyzers, and the particle core mobility provides diagnostic 
information different from particle size and concentration 
distribution. 
ADDITIONAL EXAMPLES 
In the following Examples, all aqueous samples are 
prepared in a 9.1 D2O/H2O saline buffer, concentrated to a 
viscosity of 1.20 cp at 37° C. The raw data are in the form 
of a multi exponential decay curve. The individual relax 
ation time constants are deconvoluted using an inverse 
Laplacian transform calculation as implemented in the pub 
lic domain program CONTIN. 
Lipoprotein Lipid Core Mixtures 
A CONTIN profile of triolein, the most abundant TG in 
lipoproteins, is shown in FIG. 4. Each T (or TV) corre 
sponds to a mobility domain of the triglyceride molecule. A 
VLDL like lipid core with 80% TG and 20% CE shows a 
similar profile (FIG. 5) but is shifted slightly to the left, 
indicating a less mobile, more vicious environment. The 
LDL like lipid core (FIG. 6) composed of 80% CE and 20% 
TG exhibited lower T or TV values indicating reduced 
mobility. This trend resembles that observed with physi 
ological lipoprotein particles with differences in TG/CE 
ratios. TV values for lipid mixtures are Summarized in 
Table 1. 
US 9,551,768 B2 
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TABLE 1. 
TV times in Ins 
Fast Medium Slow Other 5 
100% TO 347 155 79 8 
80% to 20% CL 303 141 70 25, 5 
(VLDL Core) 
20% to 80% CL 183 92 45 19, 9, 4 
(LDL Core) 
10 
Fractionated Lipoproteins and Serum Proteins 
FIG. 7 shows the TV profiles for albumin (“HAS”), LDL 
plus albumin and VLDL plus albumin. Although all of the 
profiles display fast decaying components in the range of 1 
2-50 ms, there are TV values above 50 ms that are unique 
to individual lipoprotein classes 
Whole Human Serum 
De-identified samples of whole human serum, represent 
ing various metabolic and disease states were obtained from 
Pitt County Memorial Hospital (Greenville, N.C., USA). As 
seen in FIG. 8 variability was observed in lipoprotein TV 
values. Patient samples with a higher HbA1c, indicative of 
poorly managed Type 2 Diabetes Mellitus, have increased 
T or TV values suggesting that the lipoprotein particles 
have increasingly mobile, TG-rich lipid cores versus non 
diabetic patients. 
Results: FIG. 9 shows the remodeling healthy non-dia 
betic Subject ingested a liquid meal that contained 50 grams 
of lipid following a 16 hour fast, after which blood was 
drawn every hour for 8 hours. The NMR data are shown in 
FIG. 4b at 0 hour (fasting) and other time points after the 
meal. As lipoprotein remodeling occurs and the particles 
become TG rich, the TV peak shifts to the right indicating 
an increase in lipid core mobility. Table 2 shows standard 






















































Benchtop TD-NMR appears to provide unique informa 
tion about LDL and VLDL particle properties reflective of 
different states of normal and abnormal metabolism. This 
10 
approach holds promise for translation from the research lab 
into the clinical setting as the measurements are performed 
on whole human serum and are relatively simple, inexpen 
sive and non-invasive. 
In the drawings and specification there has been set forth 
a preferred embodiment of the invention, and although 
specific terms have been employed, they are used in a 
generic and descriptive sense only and not for purposes of 
limitation, the scope of the invention being defined in the 
claims. 
The invention claimed is: 
1. A method for assessing cardiovascular disease risk 
based upon the properties of protein and lipoprotein ele 
ments in a sample, the method comprising the steps of: 
conducting a low-speed centrifugation of a human blood 
sample obtained after clotting: 
placing a small Volume of the unfractionated human 
serum sample into a low field TD-NMR spectrometer 
tuned to measure hydrogen-1, 
applying a series of CPMG spin echo pulse sequences 
with intermittent delays to the sample in order to 
measure spin-spin relaxation time constants from the 
time-domain decay of the signal, without the use of 
chemical shifts and without converting data into the 
frequency domain by Fourier transform or other means; 
at least partially suppressing the water signal from the 
sample by inserting a 180-degree inversion pulse fol 
lowed by a delay prior to the CMPG sequence used to 
record relaxation time constants in the time domain; 
analyzing the exponentially decaying NMR signal from 
the sample in the time domain using multi-exponential 
analysis; and 
comparing differences in the relaxation time constants for 
lipoprotein classes selected from the group consisting 
of LDL, HDL, and VLDL in the sample to measure 
mobility differences in the oil phases within the core 
compartment of the selected lipoprotein particles which 
are in turn reflective of increased cardiovascular dis 
ease risk or active disease and in which the comparison 
of relaxation time constants is made to other relaxation 
time constants within a group consisting of samples 
from the same human Subject and samples among 
different human subjects. 
2. A method according to claim 1 comprising using 
between about 0.2 and -0.6 mL of the sample. 
3. A method according to claim 1 further comprising 
normalizing the Viscosity of the sample. 
k k k k k 
